Biomedical sciences

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Retrieved on: 
星期一, 五月 6, 2024
Research fellow, Metabolism, Economics, AstraZeneca, Biomedical sciences, Inflammation, Princeton University, GSK plc, Roche, Mount Sinai Hospital, Harvard Medical School, Form 6-K, Phi Beta Kappa, Therapy, Physician, Columbia University, IPO, Perella Weinberg Partners, Former, Wellesley College, Stanford University, Business development, Stem cell, Neoplasm, Columbia Business School, Pharmaceutical industry

The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

Key Points: 
  • The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
  • "When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aspired to involve leading figures in the biotech sector.
  • Previously, Lauren co-founded Tokum Capital Management, a global institutional healthcare fund, and successfully managed its merger with Perella Weinberg Partners.
  • Todd is also a principal in Wider Film Projects, a documentary film company focused on producing films with sociopolitical resonance that have won Academy, Emmy and Peabody Awards.

American Kidney Fund Awards Fellowships to Researchers Studying Acute Interstitial Nephritis and Pulmonary Hypertension in Kidney Patients

Retrieved on: 
星期四, 四月 11, 2024
Urine, Kidney disease, Cancer, Biomedical sciences, Inflammation, Biostatistics, MD–PhD, Kidney, Research fellow, Pulmonary hypertension, Nephritis, Risk, Hope, Blood, Clinical scientist, Epidemiology, Death, Immunotherapy, Clinical and Translational Science, MD, Research, Yale University, CSN, CKD, American Kidney Fund, Patient, Kidney transplantation, Bachelor of Arts, Dialysis, AKF, Diagnosis, Immune system, Chronic kidney disease, Heart failure, Pharmaceutical industry

However, it is common in patients with CKD, with approximately 21% of CKD patients having pulmonary hypertension.

Key Points: 
  • However, it is common in patients with CKD, with approximately 21% of CKD patients having pulmonary hypertension.
  • "Pulmonary hypertension is a common and underrecognized issue for patients with chronic kidney disease,” said Dr. Tuttle.
  • “Through this study, I plan to identify new risk factors for pulmonary hypertension in patients with chronic kidney disease.
  • Her current research focuses on the development of pulmonary hypertension in patients with chronic kidney disease.

Dermatology and Laser Center of Charleston Joins Epiphany Dermatology

Retrieved on: 
星期一, 四月 22, 2024
Alternative Medicine, Surgery, General Health, Health, Consumer, Cosmetics, Other Consumer, Other Health, Medical school, Biomedical sciences, State university system, Partnership, Skin care, Entrepreneurship, Patient, Cleveland Clinic, Marketing, SUNY

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in South Carolina through its partnership with Todd Schlesinger, MD, and his team at Dermatology and Laser Center of Charleston, based in Charleston, South Carolina.

Key Points: 
  • Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in South Carolina through its partnership with Todd Schlesinger, MD, and his team at Dermatology and Laser Center of Charleston, based in Charleston, South Carolina.
  • Founded in 2005 by Dr. Schlesinger, Dermatology and Laser Center of Charleston has a solid reputation of providing high-quality dermatology and cosmetic services to patients in Charleston, SC, and surrounding communities.
  • I look forward to helping Epiphany maintain its high standards of quality patient care.”
    Gheorghe Pusta, Co-Founder and Chief Executive Officer of Epiphany said, “We are excited to welcome Dr. Schlesinger and his team to Epiphany.
  • Epiphany also benefits from the clinical expertise of Dermatology and Laser Center of Charleston’s team, as best practices are collaboratively shared across the Epiphany network.

Helping to Diagnose and Treat Heart Disease, Tumors, and Other Conditions at the Intersection of Physics, Molecular Biology, and High-Performance Computing

Retrieved on: 
星期三, 四月 24, 2024
CPU, Palace Hotel, Cancer, Biomedical sciences, Grace Murray Hopper Award, Corniche (Abu Dhabi), Applied physics, National academy, Infosys, Computer science, Disease, Cell, ACM, System, Hope, Oncology, Blood, Health, Heart, Friction, IEEE, Amanda Randles, Computer, Doctor of Philosophy, Research, ACM Prize in Computing, Biophysics, 3D, NSF, Duke University, Patient, APR, Physiology, Neoplasm, Cardiology, Harvard University, Technical, MIT, Medical imaging

NEW YORK, April 24, 2024 /PRNewswire/ -- ACM, the Association for Computing Machinery, has named Amanda Randles the recipient of the ACM Prize in Computing for groundbreaking contributions to computational health through innovative algorithms, tools, and high-performance computing methods for diagnosing and treating a variety of human diseases.

Key Points: 
  • Randles has developed computational tools to enable 3D blood flow simulations to diagnose and treat human diseases.
  • The ACM Prize in Computing recognizes early-to-mid-career computer scientists whose research contributions have fundamental impact and broad implications.
  • The award carries a prize of $250,000 from an endowment provided by Infosys Ltd., a global leader in next-generation digital services and consulting.
  • She also developed a new way to model the human heart, which allowed heart simulations for a large group of patients.

Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million

Retrieved on: 
星期二, 四月 16, 2024
Leg, Media, Biomedical sciences, Incubator, Financial endowment, Health, BLEG, Sycamore, Growth, Drug discovery, Acquisition, Bukit Bintang, CO2, Biotechnology, Airline

MELBOURNE, Fla., April 16, 2024 /PRNewswire/ -- Branded Legacy, Inc, (OTC.PK: BLEG) a leading provider of innovative wellness products, is pleased to announce a net income for the fiscal year 2023 of $3,825,527, a substantial increase driven by the strategic retirement of over 2.4 billion shares. As they forge into 2024, the company has signed multiple on-going white label contracts, poised to further enhance our revenue and profitability for the coming year and beyond.

Key Points: 
  • "2023 was a year of substantial growth and strategic repositioning for Branded Legacy.
  • This acquisition not only secured assets exceeding $2 million but also integrates key personnel vital for advancing their clinical trials.
  • The company's recent strategic endeavors include the acquisition of several companies, bringing over $3.7 million worth of advanced scientific equipment and inventory.
  • Branded Legacy, Inc. is poised to continue its trajectory of growth, innovation, and market leadership in the biotech and wellness industries.

Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain

Retrieved on: 
星期四, 三月 21, 2024
Psilocybin, University of Guelph, Research, Certification, Brain, Learning, University, Memory, Associate, Partnership, Patient, Knowledge, Fungus, Agriculture, Anxiety, Adolescence, Autism spectrum, Biomedical sciences, Spectrum, ASD, Biomass, Pharmaceutical industry

This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.

Key Points: 
  • This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
  • The collaborative preclinical research will focus on exploring and standardizing the chemical diversity of Rose Hill’s psilocybin mushrooms, legally imported from Jamaica to Canada for the work.
  • Additionally, utilizing a rodent model, the study will investigate their potential application in Autism Spectrum Disorders (ASD).
  • Psilocybin mushrooms, known for their psychoactive properties, have long captivated the scientific community's interest due to their potential therapeutic applications and unique biochemical composition.

PCOM, The Wistar Institute Announce Cancer Biology Graduate Program

Retrieved on: 
星期三, 三月 20, 2024
Wistar Institute, Drug discovery, Patient, PCOM, Research, News, Cancer, Doctor of Philosophy, Faculty, Student, Drug development, Biomedical sciences, School

Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.

Key Points: 
  • Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.
  • , Wistar President and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor.
  • The Cancer Biology Graduate Program—jointly administered by Wistar and PCOM—will train individuals for a successful academic or industrial career in cancer biology and drug development.
  • At the conclusion of their studies, successful candidates will be granted a Ph.D. in cancer biology from PCOM.

Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024

Retrieved on: 
星期一, 三月 18, 2024
Ovarian cancer, Brain, Immunotherapy, Colorectal cancer, Patient, Lead, Research, Doctor of Philosophy, University of Adelaide, University, GMP, AACR, Biomedical sciences, Stomach, Liver, Pharmaceutical industry

ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.

Key Points: 
  • ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
  • “We are looking forward to sharing data related to our LRG-5 targeted CAR-T program in three poster presentations at the upcoming AACR annual meeting.
  • One of the posters will highlight the GMP manufacturing and testing findings for our lead LGR5-targeted CAR-T cell therapy candidate CNA3103, that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of adult patients with metastatic colorectal cancer,” stated Deborah Rathjen, PhD, Carina’s Chief Executive Officer.
  • “Our research team will also be presenting preclinical data that demonstrate the potential to develop our LGR5-targeting CAR-T cells as a novel immunotherapy for ovarian cancer and that expand the preclinical body of evidence across a diverse range of cancer families, including ovarian, brain, liver, and stomach, where LGR5-targeting CAR-T cells may be harnessed.”
    Lead Author: Jade Foeng, PhD, Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, The University of Adelaide, South Australia

Zephyr AI Raises $111 Million in Series A Financing

Retrieved on: 
星期三, 三月 13, 2024
Technology, Clinical Trials, Professional Services, Cardiology, Software, General Health, Health, Data Management, Oncology, Artificial Intelligence, Algorithm, ARU, Gene expression, Entrepreneurship, Eli Lilly and Company, Patient, LLP, Nature, Revolution LLC, Cooley LLP, Medicine, Abstract, AACR, Drug development, Ecosystem, Biomedical sciences, Interim, Machine learning, Collection, Artificial intelligence, Pharmaceutical industry

Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.

Key Points: 
  • Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.
  • We must do better,” said Grant Verstandig, Zephyr AI’s Co-Founder and Executive Chairman.
  • “At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data.
  • Cooley LLP served as legal counsel for Zephyr AI.

Open Call: Vilcek Foundation to Award $150,000 in Prizes to Immigrant Scientists in 2025

Retrieved on: 
星期一, 三月 25, 2024
IRS, Culture, Organization, Rheumatoid arthritis, Gene editing, Foundation (nonprofit), Humanities, Biomedical Research, Vilcek Foundation, Research, History, Messenger, Jan Vilček, Nobel Prize, Biomedical sciences, CRISPR, Creative, Therapy, Family, Parent, Medicine, Pharmaceutical industry

NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation has announced an open call for applications for the 2025 Vilcek Prizes for Creative Promise in Science. Three prizes of $50,000 each will be awarded to young immigrant scientists in the United States whose early career work represents a significant contribution to their field. Applications will be accepted through June 10, 2024, at 5:00pm ET.

Key Points: 
  • The Vilcek Foundation will accept applications for the 2025 Vilcek Prizes for Creative Promise in Biomedical Science through June 10, 2024.
  • NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation has announced an open call for applications for the 2025 Vilcek Prizes for Creative Promise in Science .
  • The Vilcek Prizes for Creative Promise are awarded to immigrant professionals living and working in the United States.
  • The Vilcek Prizes for Creative Promise are a part of the Vilcek Foundation Prizes program.